Compare AbbVie Inc (ABBV) vs Matson Inc (MATX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Matson Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Matson Inc trades at $202.65 (market cap $6.01B). The key difference: AbbVie Inc is far larger — about 74.9× Matson Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MATX | |
|---|---|---|
Market Cap | $449.91B | $6.01B |
Sector | Health | Technology |
52-Week High | $261.07 | $204.53 |
52-Week Low | $184.85 | $88.05 |
Enterprise Value | $513.38B | $6.61B |
Dividend Yield | 2.72% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Matson (MATX) trades at $204.53, up 0.49% with strong technical momentum near resistance at $206. The stock shows robust fundamentals with consistent earnings beats, a 12.92% net margin, and shareholder-friendly actions including dividend increases and share buybacks. Recent news highlights the company's niche Pacific shipping advantages and operational efficiency gains.
Outlook remains positive given analyst consensus (64% buy ratings) and strong profitability metrics, though risks include shipping rate volatility and macroeconomic sensitivity. The current valuation at 15.17x P/E appears reasonable for a company with double-digit ROE and dividend growth, positioning MATX as a quality mid-cap transportation play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
